Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial

INTRODUCTION: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial data over 4 weeks for dulaglutide (0.75 mg) versus placebo after a standardized test meal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Inoue, Megumi, Shiramoto, Masanari, Oura, Tomonori, Nasu, Risa, Nakano, Masako, Takeuchi, Masakazu
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6531535/
https://ncbi.nlm.nih.gov/pubmed/30949907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0605-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky